| Drug Name |
Treprostinil sodium |
| Drug ID |
BADD_D02269 |
| Description |
Treprostinil is a synthetic analogue of prostacyclin, used to treat pulmonary hypertension. |
| Indications and Usage |
For use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. |
| Marketing Status |
approved; investigational |
| ATC Code |
B01AC21 |
| DrugBank ID |
DB00374
|
| KEGG ID |
D08628
|
| MeSH ID |
C427248
|
| PubChem ID |
23663413
|
| TTD Drug ID |
D01WUA
|
| NDC Product Code |
68245-0009; 14501-0016; 40016-009; 58159-040; 82231-115; 54893-0022 |
| UNII |
7JZ75N2NT6
|
| Synonyms |
treprostinil | ((1R,2R,3AS,9AS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3A,4,9,9A-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate | treprostinil sodium | trepostinil sodium | Orenitram | UT-15 | UT-15C | Remodulin | treprostinil diolamine | treprostinil diolamin | treprostinil diethanolamine |
